Erythropoiesis stimulating agents approaches to modulate activity
Angus M Sinclair Amgen Inc, Thousand Oaks, CA, USA Abstract: Recombinant human erythropoietin (rHuEPO), such as the approved agents epoetin alfa and epoetin beta, has been used successfully for over 20 years to treat anemia in millions of patients. However, due to the relatively short half-life of t...
Enregistré dans:
Auteur principal: | Sinclair AM |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2013
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/c50b66a52a4947e6b18f0a2108cca0f7 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Differential modulation of angiogenesis by erythropoiesis-stimulating agents in a mouse model of ischaemic retinopathy.
par: Carmel M McVicar, et autres
Publié: (2010) -
Effect of erythropoiesis-stimulating agents on blood pressure in pre-dialysis patients.
par: Marit M Suttorp, et autres
Publié: (2013) -
Managing chemotherapy induced anemia with darbepoetin alfa and other erythropoiesis stimulating agents: a nurse's perspective
par: Derbyshire L, et autres
Publié: (2013) -
The effect of erythropoietin on normal and neoplastic cells
par: Elliott S, et autres
Publié: (2012) -
New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents
par: Ara Metjian, et autres
Publié: (2009)